ReviewFrontiers in immunology2026
Bioelectronic modulation of the thymic "genetic mirror": 448 kHz radiofrequency stimulation as a novel strategy for immune tolerance induction in type 1 diabetes.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 1 Diabetes Mellitus (T1DM) arises from a fundamental breakdown of central immune tolerance within the thymus. Medullary thymic epithelial cells (mTECs) express the Autoimmune Regulator (AIRE) protein, which drives the promiscuous transcription of peripheral tissue-restricted antigens - including insulin - thereby creating a "genetic mirror" essential for the clonal deletion of autoreactive T-cells. Genetic susceptibility loci that reduce intrathymic insulin expression allow high-affinity insulin-reactive T-cells to escape negative selection and enter the periphery, where they ultimately orchestrate the progressive destruction of pancreatic β-cells. Despite decades of research, no therapeutic strategy has yet succeeded in restoring this upstream tolerogenic defect at its source. Hypothesis: I hypothesise that the thymic microenvironment can be bioelectronically reprogrammed to re-establish central immune tolerance in T1DM. Specifically, I propose that non-invasive application of 448 kHz radiofrequency (RF) fields, delivered via a wearable smart patch using subthermal Capacitive-Resistive Electric Transfer (CRET), can selectively upregulate Proposed mechanism: The 448 kHz RF field is hypothesised to interact with L-type voltage-gated calcium channels (Cav1.2/Cav1.3) on mTEC membranes, inducing a controlled, subthermal Ca² Significance: This approach represents a conceptual shift from peripheral immunosuppression or symptomatic glycaemic management towards upstream, disease-modifying bioelectronic intervention. By targeting the embryologically conserved thymic-pancreatic axis, the 448 kHz CRET strategy offers a non-invasive, paediatric-compatible platform to arrest the autoimmune cascade at its immunological origin, with potential implications for the prevention and early interception of T1DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.